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o.com (M.M. AnnAbstract A stability-indicating high-performance liquid chromatographic method was developed
and validated for the determination of Letrozole in tablet dosage forms. Reversed-phase chromato-
graphy was performed on Shimadzu Model LC-Class-Vp with Lichrocart/Lichrosphere 100 C-18
(250 mm 4.6 mm, 5 mm particle size) column with methanol: tetra butyl ammonium hydrogen
sulfate (80:20V/V) as mobile phase at a ﬂow rate of 1 mL/min with UV detection at 240 nm. Linearity
was observed in the concentration range of 0.5–150 mg/mL (R2¼0.9998) with regression equation
y¼102582xþ43185. The limit of quantitation (LOQ) and limit of detection (LOD) were found to be
0.043 and 0.012 mg/mL respectively. The forced degradation studies were performed by using HCl,
NaOH, H2O2, thermal and UV radiation. Letrozole is more sensitive towards alkaline conditions and
very much resistant towards acidic, oxidative and photolytic degradations. The method was validated
as per ICH guidelines. The RSD for intra-day (0.78–0.97) and inter-day (0.86–0.96) precision were
found to be lesser than 1%. The percentage recovery was in good agreement with the labeled amount
in the pharmaceutical formulations and the method is simple, speciﬁc, precise and accurate for the
determination of Letrozole in pharmaceutical formulations.
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1. Introduction
Letrozole (Fig. 1), chemically known as 4-[(4-cyanophenyl)-(1, 2,
4-triazol-1-yl) methyl] benzonitrile [1], is used for the treatment of
estrogen-dependent breast cancers [2]. It is an oral non-steroidal
aromatase inhibitor that has been introduced for the adjuvant
treatment of hormonally-responsive breast cancer. It is readily
and completely absorbed from the gastrointestinal tract. It is
slowly metabolized in the liver to an inactive carbinol metabolite,
which is then excreted as glucoronide in the urine [3].
Figure 1 Chemical structure of Letrozole.
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dosage form should be developed and validated. To date, all
analytical methods described in literature for the determi-
nation of Letrozole in biological and other matrices involve
spectrophotometry [4–5], liquid chromatography [6–11],
the microarray approach [12], capillary gas chromato-
graphic method with ﬂame ionization detector [13] and
gas chromatography–mass spectrometry [14] methods. Ping
et al. determined the related substances in Letrozole and
in its tablet dosage forms using HPLC and TLC [15]
methods.
Very few methods are reported in the literature and no
stability indicating method is available in the ofﬁcial compen-
dia using HPLC for analyzing of Letrozole in dosage forms.
Quality control of pharmaceutical products requires identiﬁ-
cation and quantiﬁcation of the active ingredient and its
impurities for safety and efﬁcacy reasons. Impurities and
potential degradation products that may exist in medicines
can change the chemical, pharmacological and toxicological
properties of the product.
The reported methods in the literature suffer from one or
the other disadvantage such as poor sensitivity, very narrow
linearity range, scrupulous control of experimental vari-
ables, etc. Since pharmacopoeias do not describe a suitable
method for the determination of Letrozole in pharmaceu-
tical formulations, in the present work we developed simple,
rapid and accurate reverse phase liquid chromatographic
method for the determination of Letrozole tablets as an
alternative method. Apart from this, it can be used for
assays of Letrozole in biological ﬂuids or in pharmacoki-
netic investigations.2. Experimental
2.1. Chemicals and solutions
Letrozole standard (purity 99.80%) was obtained from
Shantha Biotech (India). Methanol (HPLC grade), tetra butyl
ammonium hydrogen sulfate (TBAHS), sodium hydroxide
(NaOH) and hydrochloric acid (HCl) and hydrogen peroxide
(H2O2) were obtained from Merck (India). HPLC grade water
was obtained from Gen Pure system (TKA, Germany).
Letrozole is available commercially with brand names LETO-
CORs (Chandrabhagat Pharma), LETORIPEs (Miracallis)
as tablets with a label claim of 2.5 mg drug was purchased
commercially. All chemicals were of an analytical grade and
used as received.2.2. HPLC instrumentation and conditions
Chromatographic separation was achieved using a Lichrocart/
Lichrosphere 100 C-18 (250 mm 4.6 mm i.d., 5 mm particle
size) column of Shimadzu Model LC-Class-Vp version 6.12
SPI, equipped with UV–VIS detector Model SPD-10 A main-
tained at 25 1C. Isocratic elution was performed using metha-
nol and 10 mM TBAHS (80:20, v/v). The overall run time was
10 min and the ﬂow rate was 1.0 mL/min .20 ml of sample was
injected into the HPLC system.
The mobile phase was prepared by accurately weighing and
transferring 3.3954 g of TBAHS (10 mM) (pH 3.4) in to a
1000 mL volumetric ﬂask, dissolving and diluting to volume
with HPLC grade water.
Letrozole stock solution (1000 mg/mL) was prepared by
accurately weighing 25 mg of Letrozole in a 25 mL amber
volumetric ﬂask and making up to volume with mobile phase.
Working solutions for HPLC injections were prepared on a
daily basis from the stock solution in a solvent mixture of
methanol and 10 mM TBAHS (80:20, v/v) (mobile phase).
Solutions were ﬁltered through a 0.45 mm membrane ﬁlter
prior to injection.
Twenty tablets were purchased from the local market,
weighed and crushed to a ﬁne powder. An aliquot of powder
equivalent to the weight of 25 mg Letrozole was accurately
weighed into a 25 mL volumetric ﬂask and made up to volume
with methanol. The volumetric ﬂask was sonicated for 30 min
to enable complete dissolution of Letrozole. The solution was
ﬁltered and aliquots of ﬁltrate were transferred using a pipette
into 5 mL volumetric ﬂasks and made up to volume with
mobile phase to yield a concentration of 20 mg/mL. These
solutions were ﬁltered through a 0.45 mm nylon ﬁlter before
injections.2.3. Forced degradation studies/speciﬁcity
Forced degradation studies were performed to evaluate the
stability indicating properties and speciﬁcity of the method
[16]. All solutions for use in stress studies were prepared at an
initial concentration of 1 mg/mL of Letrozole and reﬂuxed for
30 min at 80 1C. All samples were then diluted in mobile phase
to give a ﬁnal concentration of 20 mg/mL and ﬁltered before
injection.2.3.1. Acid and alkali degradation studies
Acid decomposition was carried out in 0.1 M HCl at a
concentration of 1.0 mg/mL Letrozole and after reﬂuxation
for 30 min at 80 1C the stressed sample was cooled, neutralized
and diluted with mobile phase.
Similarly stress studies in alkaline conditions were con-
ducted using a concentration of 1.0 mg/mL in 0.1 M NaOH
and reﬂuxed for 30 min at 80 1C. After cooling the solution
was neutralized and diluted with mobile phase.2.3.2. Oxidation
Solutions for oxidative stress studies were prepared using 3%
H2O2 at a concentration of 1 mg/mL of Letrozole and after
reﬂuxation for 30 min at 80 1C on the thermostat the sample
solution was cooled and diluted accordingly with the
mobile phase.
M.M. Annapurna et al.3002.3.3. Thermal degradation study
For thermal stress testing, the drug solution (1 mg/mL) was
heated in thermostat at 80 1C for 30 min, cooled and used.
2.3.4. Photo stability
The drug solution (1 mg/mL) for photo stability testing was
exposed to UV light for 1 h (365 nm) UV light chamber and
analyzed.
2.4. Method validation
The method was validated for the following parameters:
system suitability, linearity, limit of quantitation (LOQ), limit
of detection (LOD), precision, accuracy, selectivity and
robustness [17].
2.4.1. Precision
The intra-day precision of the assay method was evaluated by
carrying out 9 independent assays of a test sample of Letrozole
at three concentration levels (10, 20 and 50 mg/mL) (n¼3)
against a qualiﬁed reference standard. The % RSD of three
obtained assay values at three different concentration levels
was calculated.
The inter–day precision study was performed on three
different days i.e. day 1, day 2 and day 3 at three different
concentration levels (10, 20 and 50 mg/mL) and each value is the
average of three determinations (n¼3). The % RSD of three
obtained assay values on three different days was calculated.
2.4.2. LOQ and LOD
The LOQ and LOD were based on the standard deviation of
the response and the slope of the constructed calibration curve
(n¼3), as described in International Conference on Harmo-
nization guidelines Q2 (R1) [17].Table 1 Comparison of the performance characteristics of the p
Serial no. Method/reagent l (nm) Linea
1. Spectrophotometry 238 2–20
2. Spectrophotometry 240 1–10
3. HPLC/
Water:acetonitrile:methanol
(50:30:20, v/v/v)
240 1–50
4. HPLC (bioanalytical
method) / Acetonitrile:
phosphate buffer (pH 7.0)
230 and 295 -
5. HPLC/ Acetonitrile and
phosphate buffer (pH 7.8)
(70:30, v/v)
232 10–10
6. HPLC (bioanalytical
method)/Acetonitrile and
phosphate buffer (pH 5.5)
(35:65, v/v)
230 and 295 -
7. HPLC/ Methanol:tetra
butyl ammonium hydrogen
sulfate (10 mM) (80:20, v/v)
240 0.5–152.4.3. Linearity
Linearity test solutions for the assay method were prepared
from a stock solution at eleven concentration levels of the
assay analyte concentration (0.5, 1, 2, 5, 10, 20, 50, 80, 100,
120 and 150 mg/mL). 20 mL of each solution was injected into
the HPLC system and the peak area of the chromatogram
obtained was noted.
The solutions extracted from the marketed formulations
were injected into the HPLC system and the peak area of the
chromatograms was noted. The analytical curve was eval-
uated on three different days. The peak area vs. concentra-
tion data was analyzed with least squares linear regression.
The slope and y-intercept of the calibration curve was
reported.2.4.4. Accuracy
The accuracy of the assay method was evaluated in triplicate
at three concentration levels (80, 100 and 120%), and the
percentage recoveries were calculated. Standard addition and
recovery experiments were conducted to determine the accu-
racy of the method for the quantiﬁcation of Letrozole in the
drug product. The study was carried out in triplicate at 36, 40
and 44 mg/mL. The percentage recovery in each case was
calculated.2.4.5. Robustness
The robustness of the assay method was established by
introducing small changes in the HPLC conditions which
included wavelength (238 and 242 nm), percentage of metha-
nol in the mobile phase (82% and 78%), ﬂow rate (0.9 and
1.1 mL/min) and pH (3.3 and 3.5). Robustness of the method
was studied using six replicates at a concentration level of
20 mg/mL of Letrozole.resent method with the published methods.
rity (mg/mL) Remarks Ref.
Very narrow range [4]
Very narrow range [5]
Narrow linearity range and
use of three solvents
[6]
Liquid–solid extraction with
ﬂuorescence detection
[7]
0 Limited linearity range and
PDA detector used
[8]
Liquid–solid extraction with
ﬂuorescence detection
[9]
0 Wide linearity range. No
extra reagents for pH
adjustment. Simple,
sensitive and stability
indicating method
Present work
Figure 2 Representative chromatograms of Letrozole (20 mg/mL) [A], LETOCORs (2.5 mg) [B], and LETORIPEs (2.5 mg) [C].
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The solution stability of Letrozole in the assay method was
carried out by leaving both the sample and reference
standard solutions in tightly capped volumetric ﬂasks at
room temperature for 48 h. The same sample solutions were
assayed at 12 h intervals over the study period. The mobile
phase stability was also assessed by assaying the freshly
prepared sample solutions against freshly prepared reference
standard solutions at 12 h intervals up to 48 h. The prepared
mobile phase remained constant during the study period. The
%RSD of the Letrozole assay was calculated for the mobile
phase and solution stability experiments. An additional study
was carried out using the stock solution by storing it in a
tightly capped volumetric ﬂask at 4 1C.3. Results and discussion
The present proposed method is more simple, precise and
accurate in comparison to the reported methods in the literature
(Table 1). The linearity range for the methods reported in the
literature was narrow and some of the methods were applicable
only for bioanalytical determination of Letrozole. The present
developed method is more sensitive and can be used in a wide
concentration range for the determination of Letrozole in
pharmaceutical formulations. The complete separation of the
analytes was accomplished in less than 10 min and the method
has been successfully used to perform long-term and accelerate
stability studies of Letrozole formulations.
The present method is a stability indicating RP-HPLC
method which was not reported earlier. The present
stability-indicating method for the determination of Letro-
zole in pharmaceutical formulations is speciﬁc because the
drug peak was well separated even in the presence of
degradation products. Overall, the data demonstrated that
the excipients and the degradation products did not
interfere with the Letrozole peak, indicating the selectivity
of the method.
Quantiﬁcation was achieved with UV detection at 240 nm
based on peak area (Fig. 2A). The main objective of the
chromatographic method development was to separate the
degradation products which were obtained from the stress
studies from the Letrozole peak. The proposed methodseparates Letrozole from all its degradation products. It is
also possible to perform a stability study for the degradation
kinetics of the drug and it permits the quantitation of
Letrozole in commercial tablets.
3.1. HPLC method development and optimization
Initially the stressed samples were analyzed using a mobile
phase consisting of methanol:TBAHS (70:30, v/v) at a ﬂow
rate of 0.8 mL/min. Under these conditions, the resolution
and peak symmetry were not satisfactory, so the mobile
phase was changed to methanol: TBAHS (80:20, v/v) at a
ﬂow rate of 1 mL/min. Using these experimental condi-
tions all peaks were well resolved with good peak shape.
Therefore, a mobile phase of methanol: TBAHS (80:20, v/
v) provided the best chromatographic response and was
used for further studies.
3.2. Method validation
3.2.1. System suitability
The system suitability test was performed to ensure that
the complete testing system was suitable for the intended
application. The parameters measured were peak area,
retention time, tailing factor, capacity factor and theore-
tical plates. In all measurements the peak area varied lesser
than 2.0%, the average retention time was 3.25 min relative
standard deviation (%RSD)¼0.15%), the capacity factor
was more than 2, theoretical plates were 4876 (more than
2000) and tailing factor was 1.24 (less than 2) for the
Letrozole peak. The proposed method offers high sensitiv-
ity and Letrozole can be detected accurately. In all the
cases, the Letrozole peak was well separated from the
degradation products.
3.2.2. Precision
The precision of the method was determined by repeat-
ability (intra-day precision) and intermediate precision
(inter-day precision) of the Letrozole standard solutions.
Repeatability was calculated by assaying three samples of
each at three different concentration levels (10, 20 and
50 mg/mL) on the same day. The inter-day precision was
Table 2 Precision study of Letrozole.
Sample no. Conc. (mg/mL) Intra-day precision Inter-day precision
Meann7SD RSD (%) Meann7SD RSD (%)
1 10 1174432710804 0.92 1166569710599 0.91
2 20 2394187718674 0.78 2449910721109 0.86
3 50 5646156754672 0.97 5746353755171 0.96
nMean of three replicates.
Figure 3 Calibration curve of Letrozole.
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different concentration levels (10, 20 and 50 mg/mL) on
three different days. The % RSD range was obtained as
0.78–0.97 and 0.86–0.96 for intra-day and inter-day preci-
sion studies, respectively (Table 2).
Because the stability of standard solutions can also affect
the robustness of analytical methods, the stability of standard
solutions of the drug substance used in this method was tested
over a long period of time. One portion of a standard solution
was kept at room temperature and the other portion was
stored under refrigeration at approximately 4 1C and the
content of these solutions was regularly compared with that
of freshly prepared solutions. No change in drug concentra-
tions was observed for solutions stored under refrigeration.
But it is recommended that the sample and standard solutions
must therefore, be freshly prepared in amber colored ﬂasks to
protect from light.3.2.3. LOQ and LOD
The LOQ and LOD were determined based on the 10 and 3.3
times the standard deviation of the response, respectively, dividedby the slope of the calibration curve. The LOQ was found to be
0.043 mg/mL and the LOD was found to be 0.012 mg/mL.
3.2.4. Linearity
The representative chromatogram for Letrozole is shown in
Fig. 2A and the chromatograms obtained from the
extracted marketed formulations are shown in Fig. 2B and
C. The calibration curve for Letrozole was linear over the
concentration range of 0.5–150 mg/mL. The data for the
peak area of Letrozole versus Letrozole concentration were
treated by linear regression analysis and the correlation
coefﬁcient (R2) of 0.9998 was obtained. The regression
equation for the calibration curve (Fig. 3) was found to be
y¼102582xþ43185.
3.2.5. Accuracy
The method accuracy was proven by the recovery test. A
known amount of Letrozole standard (20 mg/mL) was added
to aliquots of sample solutions (16, 20 and 24 mg/mL),
and then diluted to yield total concentrations as 36, 40 and
44 mg/mL as described in Table 3. The assay was repeated
(n¼9) over 3 consecutive days. The resultant % RSD for this
Stability-indicating RP-HPLC method for the determination of Letrozole 303study was found to be 0.142% with a corresponding percen-
tage recovery value of 99.51%.3.2.6. Robustness
The robustness of an analytical procedure refers to its
ability to remain unaffected by small and deliberate
variations in method parameters and provides an indica-
tion of its reliability for routine analysis [16]. The robust-
ness of the method was evaluated by assaying the same
sample under different analytical conditions deliberately
changing from the original condition. The detection wave-
length was set at 238 and 242 nm (72 nm), the ratio of
percentage of methanol: TBAHS in the mobile phase was
applied as 78:22 and 82:18 (v/v) (72%), the ﬂow rate was
set at 0.9 and 1.1 mL/min (70.1 mL/min) and the pH was
3.3 and 3.5 (70.1). The results obtained from assay of the
test solutions were not affected by varying the conditions
and were in accordance with the results for original
conditions. The % RSD value of assay determined for
the same sample under original conditions and robustness
conditions was less than 2.0%, indicating that the devel-
oped method was robust.3.2.7. Selectivity/speciﬁcity
The speciﬁcity of the developed method was determined by
injecting sample solutions (20 mg/mL) which were prepared byFigure 4 Representative chromatograms of Letrozole (20 mg/mL) on a
degradations.
Table 3 Accuracy-recovery study of Letrozole by stan-
dard-addition method.
Sample
no.
Amount of
standard
Letrozole
added (mg/mL)
Total
found
(mg/mL)
Mean
recoveryn
(%)
Meann
RSD
(%)
1 16 15.93 99.56 0.1424
2 20 19.87 99.35
3 24 23.91 99.62
nMean of three replicates.forcibly degrading under such stress conditions as heat, light,
oxidative agent, acid and base under the proposed chromato-
graphic conditions.
The stability indicating capability of the method was
established from the separation of Letrozole peak from
the degraded samples derived from the Class Vp software.
The degradation of Letrozole was found to be very similar
for both the tablets and standard. Typical chromatograms
obtained following the assay of stressed samples are shown
in Fig. 4A–E.
3.2.8. Solution stability and mobile phase stability
The %RSD of the assay of Letrozole from the solution
stability and mobile phase stability experiments was within
2%. The results of the solution and mobile phase stability
experiments conﬁrm that the sample solutions and mobile
phase used during the assays were stable up to 48 h at room
temperature and up to 3 months at 4 1C.
3.2.9. Analysis of commercial formulations (tablets)
The proposed method was applied to the determination of
Letrozole tablets (LETOCORs and LETORIPEs) and the
result of these assays yielded 99.84% and 99.72%, respec-
tively, (RSD is o2.0%). The result of the assay (Table 4)
indicates that the method is selective for the assay of Letrozole
without interference from the excipients used in these tablets
(Fig. 2B and C).
3.2.10. Forced degradation studies
Letrozole standard and tablet powder was found to be quite
stable under dry heat conditions. A slight decomposition was
seen on exposure of Letrozole drug solution to acid, oxida-
tion and heat. On the other hand, the basic solution under-
went degradation. The drug decomposition under alkaline
degradation was found to be 57.9%, indicating that the drug
is more sensitive under alkaline conditions. The cyano phenyl
group present in the Letrozole chemical structure may be
responsible for the reported alkaline degradation. Letrozole
has undergone oxidative and thermal degradation slightly,
i.e. 0.8% and 5.0%, respectively. The drug decompositioncidic [A], alkaline [B], oxidative [C], thermal [D] and photolytic [E]
Table 5 Forced degradation studies of Letrozole.
Stress conditions Drug recoveredn (%) Drug decomposedn (%)
Standard drug 100.0 -
Acidic hydrolysis 96.4 3.6
Alkaline hydrolysis 42.1 57.9
Oxidative degradation 99.2 0.8
Thermal degradation 95.0 5.0
Photolytic degradation 100.0 -
nMean of three replicates.
Table 4 Analysis of Letrozole commercial formulation (tablets).
Sample no. Formulation Labeled claim (mg) Amount foundn (mg) Label claimn7SD (%)
1 LETOCORs 2.5 2.496 99.84070.021
2 LETORIPEs 2.5 2.493 99.72070.014
nMean of three values.
M.M. Annapurna et al.304under acidic degradation was found to be 3.6% indicating
that the drug is resistant towards acidic conditions and quite
stable towards photolysis. It can be concluded that Letrozole
is more resistant towards acidic, oxidative, thermal and
photolytic conditions in comparison to alkaline conditions
(Table 5).4. Conclusion
A stability-indicating HPLC method was developed, validated
and applied for the determination of Letrozole in pharmaceu-
tical dosage forms. The developed method was validated as
per ICH guidelines and was found to be accurate, precise,
robust and speciﬁc. The chromatographic elution step is
undertaken in a short time (o4 min). No interference from
any components of pharmaceutical dosage form or degrada-
tion products was observed and the method has been success-
fully used to perform long-term and accelerate stability studies
of Letrozole formulations.
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